Tag Archives: pi3k inhibitor

Hopeful CLL commentary from Dr Bruce Cheson

Here’s a snippet from his post about the upcoming ASH (American Society of Hematology) conference in New Orleans, LA in December. My own doc, Dr Ian Flinn will be presenting on trial data with ipi-145. I can’t wait. There is a video on page one but the audio did not play well for me. Here’s page three from the article

Bumper Crop of New Agents

The rest of the studies focus on the new agents. We have several ibrutinib trials, including a single-agent study in patients with or without 17p deletion. There will be the final analysis of bendamustine and rituximab plus ibrutinib.[13] Do you need the chemotherapy? Do you need the bendamustine? There will be another abstract[14] with rituximab and ibrutinib alone.

This isn’t the only exciting drug. There are phosphoinositide (PI) 3-kinase inhibitors, which appear to be very good and are very impressive, perhaps as good as ibrutinib when you combine them with a drug like rituximab. In fact, a recent study of rituximab-idelalisib vs rituximab-placebo was closed early because of a survival advantage.

We are also going to be seeing a list of new PI 3-kinase inhibitors for the treatment of CLL: a new delta inhibitor, a new gamma inhibitor, and others. We’ll have to see which of these provides an advantage over the others, if at all. But in any event, we have great new drugs that will be changing the landscape of non-Hodgkin lymphomas, Hodgkin lymphoma, and chronic lymphocytic leukemia.

This is Bruce Cheson, signing off for Medscape Hematology. I will be back with you after the ASH meeting in New Orleans. See you there. Goodbye.

IPI-145 Market Buzz

wpid-IMG_20130905_071816.jpg

Disclosure: I take IPI-145 as part of a phase 1 clinical trial twice each day ;). I have some auto email alerts setup for google to send me about topics of interest and this one recently came to my inbox. The background is financial but the info I found interesting. The investment analysts seem to be excited about the future of this PI3K inhibitor drug under development. The full article is here (free registration req.). Here’s a snippet

Infinity Pharmaceuticals (INFI) is a drug discovery and development company based in Cambridge, MA.

The company’s lead product is IPI-145, being developed for both Hematologic malignancies and Inflammation. Investor’s focus is firmly on IPI-145 and its potential in various types of blood cancer (CLL, iNHL, MCL, T-Cell). IPI-145 is a potent, oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K).

What are PI3Ks?

PI3Ks are a family of enzymes involved in key immune cell functions. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and non-overlapping roles in key cellular functions, including cell proliferation, cell differentiation, cell migration and immunity. Therefore, inhibition of PI3K-delta and PI3K-gamma may have therapeutic potential across a broad range of blood cancers and inflammatory diseases.

IPI-145 is currently being evaluated in a Phase II, open-label study in people with indolent non-Hodgkin lymphoma (INHL), a potentially fatal blood cancer. The expansion portion of a Phase I study of IPI-145 in a broad range of blood cancers is also ongoing. The company is also exploring the potential of IPI-145 in inflammatory diseases. There is an ongoing Phase II-a study in people with mild asthma, and a planned Phase II trial in adults with rheumatoid arthritis.

IPI-145 has shown activity across a broad range of malignancies during Phase I trials

– 68% response rate in iNHL

– 86% PR response and Nodal response in CLL

Yes, you read that right. 86% PR (partial response) and nodal response in CLL.

The data suggests a shorter time to remission and higher overall response rate than Gilead’s new drug idelalisib which recently ended phase 3 clinical trials early and submitted new drug approval (NDA) request to the FDA.

The future of cancer treatment?

imageThe days of toxic chemotherapies may be slowly coming to an end as advanced research and clinical trials yield smarter drugs which interrupt specific metabolic and signalling pathways that ultimately allow the cancer/tumor cells to live and grow. In most cancers, the process of apoptosis or normal programmed cell death is broken. If this works according to plan, this drug compound, a PI3K inhibitor will do that for me and allow my bone marrow to get back to its normal job of producing new blood cells to replace those which have done their job and died – the way they were always supposed to. Please stay tuned.